Moderna Inc. (NASDAQ: MRNA) has reported positive topline results from its pivotal Phase 3 P304 trial of mRNA-1010, its quadrivalent seasonal influenza vaccine candidate. Enrolling 40,805 adults aged 50 years and older across 11 countries, the observer-blind, active-controlled study demonstrated an overall 26.6 percent relative vaccine efficacy (rVE; 95 percent CI 16.7 percent–35.4 percent) versus a licensed standard-dose comparator. Notably, strain-specific rVEs were 29.6 percent against A/H1N1, 22.2 percent against A/H3N2, and 29.1 percent against the B/Victoria lineage. Participants aged 65 and older achieved a 27.4 percent rVE, underscoring mRNA-1010’s robust performance in the population at highest risk.
Safety and tolerability mirrored earlier Phase 3 data from the IGNITE P303 study, with most solicited adverse events being mild to moderate—predominantly injection-site pain, fatigue, headache, and myalgia—and no new safety signals identified. The median follow-up was six months, allowing for assessment of both acute and sustained protection throughout the 2024–2025 influenza season, which was notably severe, with CDC estimates of 47 million illnesses, 610,000 hospitalizations, and 26,000 deaths in the U.S. alone.
Amid these clinical milestones, Moderna’s stock has shown volatility: shares surged approximately 37 percent over the past month but remain down 15 percent year to date, reflecting broader market skepticism and ongoing debates over U.S. drug-pricing reforms. Beyond influenza, Moderna continues to expand its vaccine portfolio—recently securing FDA approval of Spikevax for children aged six months to 11 years at increased COVID-19 risk, and broadening its RSV vaccine’s indication to adults 18–59 at elevated risk.
Looking ahead, Moderna plans to discuss mRNA-1010 data with regulatory agencies later this year, aiming for a faster flu-season filing, and is advancing its combination COVID-flu candidate, mRNA-1083. If approved, mRNA-1010 could set a new benchmark for seasonal influenza protection and reinforce the versatility of mRNA platforms across multiple respiratory pathogens.
Read more from benzinga.com